This drug just got the FDA's OK -- and an $89K price tag

A drug sold for years overseas to treat a rare form of muscular dystrophy was OKed Thursday by the FDA to be sold in the U.S., but it comes at a high price. The Wall Street Journal reports the now-FDA-approved deflazacort will be offered by Marathon Pharmaceuticals for $89,000 or so a year, up to 70 times its cost outside the U.S.; Marathon CFO Babar Ghias tells the Washington Post the net price will be $54,000 after rebates and discounts. Some who rely on it to treat Duchenne muscular dystrophy...
Read more: http://www.usatoday.com/story/news/health/2017/02/12/expensive-drug-muscular-dystrophy/97819936/?source=Snapzu